Asked by: Baroness Maclean of Redditch (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government by how much demand for mental health, ADHD and autism services is increasing or decreasing in each of the past five years for people aged (1) under 16, (2) 16-24, (3) 25-34, (4) 35-49, (5) 50-64, and (6) over 65.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The following table shows the number of people in contact with National Health Service funded secondary mental health, learning disabilities and autism services, in each financial year between 2020/21 and 2024/25:
Age group | 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 |
Under 16 years old | 593,297 | 776,750 | 869,206 | 915,617 | 986,814 |
16-24 years old | 499,690 | 595,233 | 642,990 | 640,187 | 678,667 |
25-34 years old | 385,511 | 438,756 | 500,668 | 542,170 | 606,461 |
35-49 years old | 424,031 | 466,396 | 525,588 | 581,642 | 661,362 |
50-64 years old | 331,311 | 357,524 | 388,097 | 418,523 | 449,505 |
65 years old and over | 563,811 | 609,373 | 647,310 | 675,575 | 685,797 |
UNKNOWN | 5,593 | 12,663 | 9,005 | 17,112 | 60,684 |
Source: Mental Health Services Data Set (MHSDS)
Notes:
The following table shows the number of people known to be in contact with NHS Talking Therapies in each financial year between 2020/21 and 2024/25:
Age group | 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 |
|
Under 16 years old | 1,222 | 1,189 | 925 | 886 | 749 |
|
16-24 years old | 360,673 | 424,826 | 398,859 | 370,377 | 350,213 |
|
25-34 years old | 487,273 | 571,094 | 563,973 | 555,142 | 543,044 |
|
35-49 years old | 437,838 | 514,275 | 537,364 | 564,755 | 583,614 |
|
50-64 years old | 265,491 | 311,633 | 332,821 | 358,120 | 366,773 |
|
65 years old and over | 89,446 | 108,885 | 123,740 | 136,297 | 140,262 |
|
Source: Improving Accessing to Psychological Therapies dataset Notes:
| ||||||
Asked by: Ben Spencer (Conservative - Runnymede and Weybridge)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with Surrey and Borders Partnership NHS Foundation Trust on meeting national targets on Autism and ADHD assessments in children.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
My Rt Hon. Friend, the Secretary of State for Health and Social Care, has regular discussions on a wide range of matters, including with trusts and integrated care boards (ICBs).
The Government has recognised that, nationally, demand for assessments for neurodevelopmental conditions such as autism and attention deficit hyperactivity disorder (ADHD) has grown significantly in recent years and that people are experiencing severe delays for accessing such assessments. The Government’s 10-Year Health Plan will make the National Health Service fit for the future and recognises the need for early intervention and support.
It is the responsibility of ICBs to make available appropriate provision to meet the health and care needs of their local population, including access to neurodevelopmental assessments.
Through the Medium-term planning framework, published 24 October, NHS England has set clear expectations for local ICBs and trusts to improve access, experience, and outcomes for autism and ADHD services over the next three years, focusing on improving quality and productivity.
Asked by: Baroness Maclean of Redditch (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what safeguards are in place to prevent the risk of overdiagnosing mental health conditions in children and young people.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises rising demand for children and young people’s mental health services.
Through the Plan for Change and our 10-Year Health Plan, we are transforming the mental health system to strengthen clinical pathways and improve access to early support, while reducing the longest waits for specialist care and tackling regional disparities.
The independent review into mental health conditions, attention deficit hyperactivity disorder, and autism is examining the drivers of rising prevalence and demand, to ensure people receive the right support, at the right time, and in the right place.
More widely, we are accelerating the rollout of mental health support teams in schools and colleges, with national coverage expected by 2029. By this spring, approximately 60% of pupils will have access to early mental health support, up from 44% in spring 2024.
Asked by: Damien Egan (Labour - Bristol North East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of Yellow Card reporting for capturing cases of Topical Steroid Withdrawal.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department, with responsibility for ensuring medicines meet appropriate standards of safety, quality, and efficacy.
In 2021, the MHRA published a Public Assessment Report (PAR), reviewing the available evidence for topical steroid withdrawal (TSW) reactions, which can be found at the following link:
To inform this report, a comprehensive review of the available evidence was undertaken. This included an assessment of data from Yellow Card reports to identify suspected spontaneous cases of TSW reactions associated with topical corticosteroids on the Yellow Card database, as well as information from the published literature and other medicines regulators. The review considered whether regulatory action was required to minimise the risk of these events.
The PAR resulted in two Drug Safety Updates in 2021 and 2024 which aimed to raise awareness on the risk of TSW reactions and introduce new labelling. Both updates are available, respectively, at the following two links:
The MHRA uses the Medical Dictionary for Regulatory Activities (MedDRA) to code suspected adverse drug reactions reported by patients and healthcare professionals via the Yellow Card scheme. MedDRA is an international, clinically validated medical terminology used by regulatory authorities and the biopharmaceutical industry throughout the entire regulatory process, from pre-marketing to post-marketing safety monitoring. MedDRA is updated twice annually, and new terms can be proposed by any MedDRA users. Following the publication of the PAR, the term “Topical steroid withdrawal reaction” was added to MedDRA as a lower level term in version 24.1 and made available to users of the Yellow Card website in February 2022 as part of routine updates. This helps to ensure that more reports pertaining to TSW reactions are appropriately captured. The MHRA continues to closely monitor Yellow Card reports submitted for suspected TSW reactions.
The MHRA continues to engage with the British Association of Dermatologist who have also released a statement, which is available at the following link:
https://cdn.bad.org.uk/uploads/2024/02/22095550/Topical-Steroid-Withdrawal-Joint-Statement.pdf
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he expects fax machines to be phased out of use in Shrewsbury and Telford Hospital NHS Trust.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
My Rt Hon. Friend, the Secretary of State for Health and Social Care, has instructed National Health Service trusts to stop using fax machines for anything other than business continuity. The trust has informed NHS England that they currently only use fax machines for administrative tasks.
NHS England will be meeting with the Shrewsbury and Telford Hospital NHS Trust to work with them on their decommissioning plans. As such, there is currently no date set for when fax machines will be phased out.
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS England on the publication date for the draft commissioning policy for Chemosaturation therapy.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department and the National Health Service in England are committed to ensuring that cancer patients have timely access to treatment and tailored medical support. In 2016, NHS England concluded that there was insufficient evidence to make chemosaturation treatment available to patients on the NHS. NHS England is currently in the early stages of policy development for chemosaturation to treat metastatic uveal melanoma where surgery to remove or destroy affected cells and tissue in the liver is not feasible.
National Institute for Health and Care Excellence (NICE) guidance recommends that chemosaturation can be used for patients with secondary liver metastases resulting from a primary ocular melanoma, provided special arrangements are in place. A special arrangements recommendation states that clinicians using the procedure should inform the clinical governance lead in their trust, tell the patient about the uncertainties regarding the safety and efficacy of the procedure, and collect further data by means of audit or research. NICE is in the process of updating its guidance, with final guidance expected on 15 October 2026. The first committee meeting, to discuss the evidence, is expected to take place on 16 April 2026. Further information is available at the following link:
https://www.nice.org.uk/guidance/indevelopment/gid-ipg10448
Asked by: Callum Anderson (Labour - Buckingham and Bletchley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what funding has been allocated to cancer care infrastructure in Buckingham and Bletchley constituency in the next three financial years.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving cancer services, including diagnostic capacity and treatment infrastructure, is a priority for the Government.
The Government is committed to meeting all three National Health Service cancer waiting time standards across England. We are committed to transforming diagnostic services and will support the NHS to meet demand through investment in new capacity, including magnetic resonance imaging and computed tomography scanners. As of December 2025, community diagnostic centres are now delivering additional tests and checks on 170 sites across the country.
The forthcoming National Cancer Plan will set out further details as to how patients across England, including in Buckingham and Bletchley, will benefit from improved diagnostic services and cancer care infrastructure.
Funding for cancer pathways is multi-layered. The integrated care board uses the core Government allocation to commission services from providers, including cancer-related activity. Specialised commissioning directs funding towards specialist areas of healthcare, such as paediatric oncology and chemotherapy.
The East of England Cancer Alliance has been allocated approximately £16 million of revenue funds for 2026/27 which will support targeted programmes of work. The process to allocate these funds is currently live. System priorities have been identified and funding requests have been submitted for consideration.
Asked by: Callum Anderson (Labour - Buckingham and Bletchley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve diagnostic services for cancer in Buckingham and Bletchley constituency.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving cancer services, including diagnostic capacity and treatment infrastructure, is a priority for the Government.
The Government is committed to meeting all three National Health Service cancer waiting time standards across England. We are committed to transforming diagnostic services and will support the NHS to meet demand through investment in new capacity, including magnetic resonance imaging and computed tomography scanners. As of December 2025, community diagnostic centres are now delivering additional tests and checks on 170 sites across the country.
The forthcoming National Cancer Plan will set out further details as to how patients across England, including in Buckingham and Bletchley, will benefit from improved diagnostic services and cancer care infrastructure.
Funding for cancer pathways is multi-layered. The integrated care board uses the core Government allocation to commission services from providers, including cancer-related activity. Specialised commissioning directs funding towards specialist areas of healthcare, such as paediatric oncology and chemotherapy.
The East of England Cancer Alliance has been allocated approximately £16 million of revenue funds for 2026/27 which will support targeted programmes of work. The process to allocate these funds is currently live. System priorities have been identified and funding requests have been submitted for consideration.
Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what consideration they have given to introducing time-limited interim access pathways for rare cancer treatments where published clinical evidence and specialist expertise already exist but routine commissioning routes are not yet in place.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers, including metastatic ocular melanoma patients, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the National Health Service will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.
The Department remains committed to ensuring that rare cancer patients, including those with metastatic ocular melanoma, have timely access to treatment and tailored medical support.
Tebentafusp is a licensed treatment for uveal melanoma and has been recommended by the National Institute for Health and Care Excellence (NICE) and funded by NHS England since December 2024. Since funding commenced, over 100 patients have been registered to start treatment. At present, NHS England is not aware of any delays in access to Tebentafusp for eligible patients.
Alongside Tebentafusp, a policy proposition for melphalan chemosaturation was accepted onto the NHS England policy development work programme in March 2025, in line with the Methods for National Clinical Policies. Development of this policy is ongoing following receipt of the external evidence review. Progress updates are published through the NHS England Clinical Commissioning Work Programme, and NICE is concurrently updating its guidance. Until revised guidance is issued, the NHS continues to follow the recommendations in the current version.
The development of a Clinical Commissioning policy will determine both if the evidence is now sufficient to enable making the treatment routinely available and, if it is, whether to allocate service development funding to implement it across the NHS in England.
NHS England’s Individual Funding Request (IFR) Policy provides the framework through which requests outside routinely commissioned arrangements are considered. The IFR framework was last reviewed in 2022 and ensures fairness, consistency, and transparency in decision‑making across all applications relating to medicines, devices, or surgical interventions that fall within NHS England’s commissioning responsibilities.
Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they have considered changes to the use of individual funding requests for rare cancer treatments, particularly the requirement for exceptionality, for patients who have no alternative clinically appropriate treatment options.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers, including metastatic ocular melanoma patients, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the National Health Service will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.
The Department remains committed to ensuring that rare cancer patients, including those with metastatic ocular melanoma, have timely access to treatment and tailored medical support.
Tebentafusp is a licensed treatment for uveal melanoma and has been recommended by the National Institute for Health and Care Excellence (NICE) and funded by NHS England since December 2024. Since funding commenced, over 100 patients have been registered to start treatment. At present, NHS England is not aware of any delays in access to Tebentafusp for eligible patients.
Alongside Tebentafusp, a policy proposition for melphalan chemosaturation was accepted onto the NHS England policy development work programme in March 2025, in line with the Methods for National Clinical Policies. Development of this policy is ongoing following receipt of the external evidence review. Progress updates are published through the NHS England Clinical Commissioning Work Programme, and NICE is concurrently updating its guidance. Until revised guidance is issued, the NHS continues to follow the recommendations in the current version.
The development of a Clinical Commissioning policy will determine both if the evidence is now sufficient to enable making the treatment routinely available and, if it is, whether to allocate service development funding to implement it across the NHS in England.
NHS England’s Individual Funding Request (IFR) Policy provides the framework through which requests outside routinely commissioned arrangements are considered. The IFR framework was last reviewed in 2022 and ensures fairness, consistency, and transparency in decision‑making across all applications relating to medicines, devices, or surgical interventions that fall within NHS England’s commissioning responsibilities.